MX2012008328A - Derivados de pirazina. - Google Patents

Derivados de pirazina.

Info

Publication number
MX2012008328A
MX2012008328A MX2012008328A MX2012008328A MX2012008328A MX 2012008328 A MX2012008328 A MX 2012008328A MX 2012008328 A MX2012008328 A MX 2012008328A MX 2012008328 A MX2012008328 A MX 2012008328A MX 2012008328 A MX2012008328 A MX 2012008328A
Authority
MX
Mexico
Prior art keywords
pyrazine derivatives
medicament
bone
pharmaceutically
manufacture
Prior art date
Application number
MX2012008328A
Other languages
English (en)
Inventor
Tao Feng
Hitesh Jayantial Sanganee
Hiroki Wada
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012008328A publication Critical patent/MX2012008328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención se refiere a derivados de pirazina de Fórmula I (ver fórmula (I)) o sales aceptables farmacéuticamente de los mismos; en donde cada uno de n, m y R tiene uno de los significados definidos anteriormente en la presente descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso en el tratamiento de trastornos o afecciones óseos.
MX2012008328A 2010-01-19 2011-01-18 Derivados de pirazina. MX2012008328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29619610P 2010-01-19 2010-01-19
PCT/GB2011/050065 WO2011089416A1 (en) 2010-01-19 2011-01-18 Pyrazine derivatives

Publications (1)

Publication Number Publication Date
MX2012008328A true MX2012008328A (es) 2012-08-08

Family

ID=43743548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008328A MX2012008328A (es) 2010-01-19 2011-01-18 Derivados de pirazina.

Country Status (14)

Country Link
US (2) US8198285B2 (es)
EP (1) EP2526097A1 (es)
JP (1) JP2013517321A (es)
KR (1) KR20120120307A (es)
CN (1) CN102812017A (es)
AR (1) AR079945A1 (es)
AU (1) AU2011208530A1 (es)
BR (1) BR112012017884A2 (es)
CA (1) CA2786520A1 (es)
MX (1) MX2012008328A (es)
RU (1) RU2012135093A (es)
TW (1) TW201130814A (es)
UY (1) UY33191A (es)
WO (1) WO2011089416A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029640A2 (pt) * 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina
EP3702443B1 (en) 2013-03-14 2022-01-19 The Brigham and Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
SK14082001A3 (sk) 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003235798A1 (en) 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2005039485A2 (en) 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20050064044A1 (en) 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
JP5330274B2 (ja) * 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Also Published As

Publication number Publication date
KR20120120307A (ko) 2012-11-01
CA2786520A1 (en) 2011-07-28
JP2013517321A (ja) 2013-05-16
RU2012135093A (ru) 2014-03-10
US8198285B2 (en) 2012-06-12
US20120022082A1 (en) 2012-01-26
AU2011208530A1 (en) 2012-08-09
WO2011089416A1 (en) 2011-07-28
AR079945A1 (es) 2012-02-29
EP2526097A1 (en) 2012-11-28
BR112012017884A2 (pt) 2019-09-24
UY33191A (es) 2011-08-31
TW201130814A (en) 2011-09-16
US20130123275A1 (en) 2013-05-16
CN102812017A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
MX2012008328A (es) Derivados de pirazina.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2012DN03328A (es)
PH12015501385A1 (en) Autotaxin inhibitors
PH12015502615B1 (en) Chemical compounds
WO2013004995A8 (en) Pyrimidinone compounds and their use
MY165624A (en) N-acylsulfonamide apoptosis promoters
MX2013011931A (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2010004491A (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
MX2014012695A (es) Derivados de isoindolona.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
NZ608116A (en) Triazine-oxadiazoles
MX343706B (es) Derivados heterocíclicos novedosos.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
PH12015501609A1 (en) Phenicol antibacterials
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
TW201613864A (en) Novel compounds
WO2013040227A3 (en) Therapeutic compounds
MX340574B (es) Imidazo pirazinas.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
GB201209587D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal